Scinovex
article Open AccessTop 10% cited

Mechanism by which metformin reduces glucose production in type 2 diabetes.

Diabetes · 2000 · Vol. 49(12) · pp. 2063–2069
Ripudaman S. HundalM KrssakSylvie DufourDidier LaurentVincent LebonVisvanathan ChandramouliSilvio E. InzucchiWilliam C. SchumannKitt Falk PetersenB R LandauGerald I. Shulman

Abstract

To examine the mechanism by which metformin lowers endogenous glucose production in type 2 diabetic patients, we studied seven type 2 diabetic subjects, with fasting hyperglycemia (15.5 +/- 1.3 mmol/l), before and after 3 months of metformin treatment. Seven healthy subjects, matched for sex, age, and BMI, served as control subjects. Rates of net hepatic glycogenolysis, estimated by 13C nuclear magnetic resonance spectroscopy, were combined with estimates of contributions to glucose production of gluconeogenesis and glycogenolysis, measured by labeling of blood glucose by 2H from ingested 2H2O. Glucose production was measured using [6,6-2H2]glucose. The rate of glucose production was twice as high in the diabetic subjects as in control subjects (0.70 +/- 0.05 vs. 0.36 +/- 0.03 mmol x m(-2) min(-1), P < 0.0001). Metformin reduced that rate by 24% (to 0.53 +/- 0.03 mmol x m(-2) x min(-1), P = 0.0009) and fasting plasma glucose concentration by 30% (to 10.8 +/- 0.9 mmol/l, P = 0.0002). The rate of gluconeogenesis was three times higher in the diabetic subjects than in the control subjects (0.59 +/- 0.03 vs. 0.18 +/- 0.03 mmol x m(-2) min(-1) and metformin reduced that rate by 36% (to 0.38 +/- 0.03 mmol x m(-2) x min(-1), P = 0.01). By the 2H2O method, there was a twofold increase in rates of gluconeogenesis in diabetic subjects (0.42 +/- 0.04 mmol m(-2) x min(-1), which decreased by 33% after metformin treatment (0.28 +/- 0.03 mmol x m(-2) x min(-1), P = 0.0002). There was no glycogen cycling in the control subjects, but in the diabetic subjects, glycogen cycling contributed to 25% of glucose production and explains the differences between the two methods used. In conclusion, patients with poorly controlled type 2 diabetes have increased rates of endogenous glucose production, which can be attributed to increased rates of gluconeogenesis. Metformin lowered the rate of glucose production in these patients through a reduction in gluconeogenesis.

Metabolism, Diabetes, and CancerDiet and metabolism studiesLiver Disease Diagnosis and TreatmentMetforminGlycogenolysisInternal medicineGluconeogenesisEndocrinologyDiabetes mellitusType 2 diabetesMedicineMetabolic control analysisGlycogen

MeSH terms

Calorimetry, IndirectDiabetes Mellitus, Type 2FemaleGluconeogenesisGlucoseGlycogenHumansHypoglycemic AgentsLiverMaleMetforminMiddle AgedMagnetic Resonance Spectroscopy
Citations
1,045
FWCI
7.69
field-weighted impact
References
42
Percentile
98%
vs. same field & year
Citations per year
Cited by
Mechanisms of Insulin Action and Insulin Resistance
Physiological Reviews · 2018 · 2,790 citations
Role of AMP-activated protein kinase in mechanism of metformin action
Journal of Clinical Investigation · 2001 · 5,364 citations
Flavones: An important scaffold for medicinal chemistry
European Journal of Medicinal Chemistry · 2014 · 520 citations
Metformin in the treatment of non‐alcoholic steatohepatitis: a pilot open label trial
Alimentary Pharmacology & Therapeutics · 2004 · 371 citations
Novel concepts in insulin regulation of hepatic gluconeogenesis
American Journal of Physiology-Endocrinology and Metabolism · 2003 · 510 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.